Prelude Therapeutics Incorporated (PRLD) P/S ratio

P/S ratio today
21.0×

Only 2 fiscal years of P/S ratio are on record here for Prelude Therapeutics Incorporated (PRLD); a history needs at least 3. Prelude Therapeutics Incorporated (PRLD) trades at 21.0× its revenue per share for fiscal 2025. Figures as of 18 Nov 2026, 01:57 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
21.0×
P/S ratio, fiscal 2025
18.4×
Change on fiscal 2024
+33.1%
Fiscal years on record
22024–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Not enough data

A history of P/S ratio needs at least 3 fiscal years; 2 are on record here for Prelude Therapeutics Incorporated. Nothing is estimated to fill the gap. What is on record is in the table below.

Prelude Therapeutics Incorporated P/S ratio, year by year

Prelude Therapeutics Incorporated (PRLD) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today21.0×—$3.32—
202518.4× 33.1% up$2.90$0.16
202413.8×—$1.27$0.09
2023——$4.27—
2022——$6.04—
2021——$12.45—
2020——$71.55—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on PRLD

Prelude Therapeutics Incorporated, figure by figure

Prelude Therapeutics Incorporated (PRLD) overview: price, valuation and scorecard

Prelude Therapeutics Incorporated P/S ratio: questions and answers

What is Prelude Therapeutics Incorporated's P/S ratio?

Prelude Therapeutics Incorporated (PRLD) trades at 21.0× its revenue per share for fiscal 2025.

How is Prelude Therapeutics Incorporated's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Prelude Therapeutics Incorporated (PRLD) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/PRLD/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.